UPDATE: Barclays Downgrades CRISPR Therapeutics (CRSP) to Equalweight
Tweet Send to a Friend
(Updated - August 9, 2022 5:34 AM EDT)
Barclays analyst Gena Wang downgraded CRISPR Therapeutics (NASDAQ: CRSP) from Overweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst Gena Wang downgraded CRISPR Therapeutics (NASDAQ: CRSP) from Overweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
